Is Scorpius Holdings, Inc. overvalued or undervalued?

As of 13 November 2017, the valuation grade for Scorpius Holdings, Inc. moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company appears to be overvalued given its negative performance metrics, including a Price to Book Value of 0.08, an EV to EBITDA of -0.65, and a Return on Equity (ROE) of -530.53%.
In comparison to its peers, Scorpius Holdings has a less favorable EV to EBITDA ratio than Lisata Therapeutics, Inc. at 0.1349 and Lipocine, Inc. at 0.3892, both of which are also classified as risky. The company's stock has dramatically underperformed against the S&P 500, with a year-to-date return of -99.61% compared to the index's 12.22%, reinforcing the notion that it is overvalued in the current market context.